特拉万星在兔脑膜炎模型中对耐青霉素肺炎球菌和金黄色葡萄球菌的疗效及动力学参数测定
Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.
作者信息
Stucki Armin, Gerber Peter, Acosta Fernando, Cottagnoud Marianne, Cottagnoud Philippe
机构信息
Department of Internal Medicine, Inselspital, Bern, Switzerland.
出版信息
Antimicrob Agents Chemother. 2006 Feb;50(2):770-3. doi: 10.1128/AAC.50.2.770-773.2006.
Abstract
The penetration of telavancin was 2% into inflamed meninges and ca. 1 per thousand into noninflamed meninges after two intravenous injections (30 mg/kg of body weight). In experimental meningitis, telavancin was significantly superior to vancomycin combined with ceftriaxone against a penicillin-resistant pneumococcal strain. Against a methicillin-sensitive staphylococcal strain, telavancin was slightly but not significantly superior to vancomycin.
摘要
经两次静脉注射（30毫克/千克体重）后，特拉万星在炎症性脑膜中的渗透率为2%，在非炎症性脑膜中的渗透率约为千分之一。在实验性脑膜炎中，针对耐青霉素肺炎球菌菌株，特拉万星显著优于万古霉素联合头孢曲松。针对甲氧西林敏感葡萄球菌菌株，特拉万星略优于万古霉素，但差异不显著。
相似文献
1
Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.特拉万星在兔脑膜炎模型中对耐青霉素肺炎球菌和金黄色葡萄球菌的疗效及动力学参数测定
Antimicrob Agents Chemother. 2006 Feb;50(2):770-3. doi: 10.1128/AAC.50.2.770-773.2006.
2
Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.替考拉宁在耐甲氧西林金黄色葡萄球菌或万古霉素中介金黄色葡萄球菌所致兔主动脉瓣心内膜炎模型中的疗效
Antimicrob Agents Chemother. 2005 Aug;49(8):3163-5. doi: 10.1128/AAC.49.8.3163-3165.2005.
3
Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis.在实验性脑膜炎中，达托霉素对甲氧西林敏感金黄色葡萄球菌的疗效优于万古霉素。
J Antimicrob Chemother. 2006 Apr;57(4):720-3. doi: 10.1093/jac/dkl007. Epub 2006 Feb 3.
4
Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.在实验性脑膜炎中，达托霉素对耐青霉素以及耐青霉素和喹诺酮的肺炎球菌具有高度疗效。
Antimicrob Agents Chemother. 2004 Oct;48(10):3928-33. doi: 10.1128/AAC.48.10.3928-3933.2004.
5
Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.在由两株耐头孢菌素肺炎链球菌引起的脑膜炎实验模型中，单独及与头孢曲松或万古霉素联合使用磷霉素的评估。
J Antimicrob Chemother. 2006 May;57(5):931-6. doi: 10.1093/jac/dkl047. Epub 2006 Feb 28.
6
Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.替考拉宁在耐甲氧西林金黄色葡萄球菌诱导的小鼠菌血症模型中的疗效。
J Antimicrob Chemother. 2006 Aug;58(2):462-5. doi: 10.1093/jac/dkl222. Epub 2006 May 30.
7
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.加拿大医院分离的金黄色葡萄球菌和链球菌的体外活性：2007-2009 年 CANWARD 研究结果。
Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.
8
Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.替考拉宁治疗耐甲氧西林金黄色葡萄球菌骨髓炎的疗效：兔模型研究
J Antimicrob Chemother. 2009 Feb;63(2):357-60. doi: 10.1093/jac/dkn490. Epub 2008 Dec 5.
9
Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.替拉万星对异质性万古霉素中介金黄色葡萄球菌（hVISA）的体外活性及菌血症动物模型的体内研究。
J Antimicrob Chemother. 2010 Apr;65(4):725-8. doi: 10.1093/jac/dkq028. Epub 2010 Feb 5.
10
Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis.万古霉素与替考拉宁治疗实验性耐甲氧西林金黄色葡萄球菌（MRSA）脑膜炎的对比研究
Int J Antimicrob Agents. 2005 Nov;26(5):412-5. doi: 10.1016/j.ijantimicag.2005.08.011. Epub 2005 Oct 10.
引用本文的文献
1
Rapid activity of telavancin against and protection against inhalation anthrax infection in the rabbit model.替考拉宁对兔模型吸入性炭疽感染的快速作用及保护作用。
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0011224. doi: 10.1128/aac.00112-24. Epub 2024 Jun 18.
2
New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.用于治疗医院获得性中枢神经系统感染的新型抗生素
Antibiotics (Basel). 2024 Jan 7;13(1):58. doi: 10.3390/antibiotics13010058.
3
Pharmacokinetics and pharmacodynamics of peptide antibiotics.肽类抗生素的药代动力学和药效学。
Adv Drug Deliv Rev. 2022 Apr;183:114171. doi: 10.1016/j.addr.2022.114171. Epub 2022 Feb 18.
4
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.特拉万星：一种新型半合成脂糖肽类药物，用于应对耐革兰氏阳性病原体的挑战。
Ther Adv Infect Dis. 2017 Mar;4(2):49-73. doi: 10.1177/2049936117690501. Epub 2017 Mar 8.
5
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.糖肽类抗生素在革兰阳性感染中的应用：比较综述。
Drugs. 2015 Dec;75(18):2073-95. doi: 10.1007/s40265-015-0505-8.
6
Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.当前针对特定革兰阳性菌的抗菌治疗概念：耐甲氧西林金黄色葡萄球菌、耐青霉素肺炎链球菌和万古霉素耐药肠球菌。
Mayo Clin Proc. 2011 Dec;86(12):1230-43. doi: 10.4065/mcp.2011.0514.
7
Treatment of Drug-resistant Pneumococcal Meningitis.耐药性肺炎球菌性脑膜炎的治疗。
Curr Infect Dis Rep. 2010 Jul;12(4):274-81. doi: 10.1007/s11908-010-0110-7.
8
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.新型糖肽类抗生素：达巴万星、奥他万星和替拉万星的比较综述。
Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000.
9
In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.替考拉宁和万古霉素对产生物膜的金黄色葡萄球菌、表皮葡萄球菌和粪肠球菌菌株的体外活性。
Antimicrob Agents Chemother. 2009 Jul;53(7):3166-9. doi: 10.1128/AAC.01642-08. Epub 2009 May 18.
10
Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.替考拉宁治疗耐糖肽金黄色葡萄球菌所致实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2007 Jul;51(7):2373-7. doi: 10.1128/AAC.01266-06. Epub 2007 May 7.
本文引用的文献
1
Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?美国肺炎链球菌的抗菌药物耐药性：我们是否已开始在某些抗菌药物类别的耐药性问题上有所转机？
Clin Infect Dis. 2005 Jul 15;41(2):139-48. doi: 10.1086/430906. Epub 2005 Jun 7.
2
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.替考拉宁在健康受试者中的药代动力学、血清抑制和杀菌活性及安全性。
Antimicrob Agents Chemother. 2005 Jan;49(1):195-201. doi: 10.1128/AAC.49.1.195-201.2005.
3
Glycopeptides in clinical development: pharmacological profile and clinical perspectives.处于临床开发阶段的糖肽类药物：药理学特征与临床前景
Curr Opin Pharmacol. 2004 Oct;4(5):471-8. doi: 10.1016/j.coph.2004.04.006.
4
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.替考拉宁（TD-6424）的体外比较活性，一种对革兰氏阳性菌具有多种作用机制的快速杀菌、浓度依赖性抗感染药物。
J Antimicrob Chemother. 2004 May;53(5):797-803. doi: 10.1093/jac/dkh156. Epub 2004 Mar 17.
5
Management of pneumococcal meningitis.肺炎球菌性脑膜炎的管理
Pediatr Infect Dis J. 2002 Jun;21(6):589-91; discussion 613-4. doi: 10.1097/00006454-200206000-00034.
6
Global antibiotic resistance in Streptococcus pneumoniae.肺炎链球菌的全球抗生素耐药性
J Antimicrob Chemother. 2002 Jul;50 Suppl:1-5. doi: 10.1093/jac/dkf801.
7
Mechanisms of pneumococcal antibiotic resistance and treatment of pneumococcal infections in 2002.2002年肺炎球菌抗生素耐药机制及肺炎球菌感染的治疗
Pediatr Ann. 2002 Apr;31(4):250-60. doi: 10.3928/0090-4481-20020401-09.
8
Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain.美罗培南单独及与万古霉素联合用于耐青霉素肺炎球菌菌株所致实验性脑膜炎的研究。
Eur J Clin Microbiol Infect Dis. 1999 Dec;18(12):866-70. doi: 10.1007/s100960050421.
9
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.左氧氟沙星与环丙沙星、氟氯西林或万古霉素治疗甲氧西林敏感或耐药金黄色葡萄球菌所致实验性心内膜炎的疗效比较
Antimicrob Agents Chemother. 1997 Aug;41(8):1662-7. doi: 10.1128/AAC.41.8.1662.
10
Epidemiology, control and treatment of multiresistant pneumococci.多重耐药肺炎球菌的流行病学、控制与治疗
Drugs. 1996;52 Suppl 2:42-6. doi: 10.2165/00003495-199600522-00009.
Zotero 插件